Alfuzosin Hydrochloride
Product Images NDC 70934-306

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 70934-306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

70934 306 30 Master Bottle Label Approval Rev A 03 19

70934 306 30 Master Bottle Label Approval Rev A 03 19
NDC: 70934-306-30 is a prescription drug. Its name is zZosin Hydrochloride and it is an extended-release tablet of 10mg strength, with a total count of 30 tablets. The manufacturer's name is not available from the text obtained by .*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This is a figure presenting the mean change from baseline in IPSS Total Symptom Score after 28 and 56 days of treatment with either placebo (N=152) or alfuzosin hydrochloride extended-release tablets (N=137), in Trial 2. The statistical significance is reported as **p < 0.01.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
The given text depicts the analysis of trial 3, showcasing the comparison between A Placebo (N=150) and Aituzosin hydrochloride extended-release tablets (N=151) on the basis of their mean change from Baseline in IPSS Total Symptom Score. It is mentioned that the treatment lasted for 28 to 56 days, and the results indicate a significant improvement with Aituzosin hydrochloride extended-release tablets. Therefore, this text provides essential information on the efficacy of the drug in managing symptoms.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This is a graph that shows the mean change from baseline in peak urine flow rate in a clinical trial. There are two groups represented: a placebo group and a group taking alfuzosin hydrochloride extended-release tablets. The graph shows a significant improvement in the peak urine flow rate in the group taking alfuzosin hydrochloride compared to the placebo group. The X-axis represents the days of treatment and the Y-axis represents the change in urine flow rate in mL/s.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
The given text appears to be from a scientific report or a research paper that includes a graph. The graph shows the mean change from baseline in peak urine flow rate over the course of 84 days of treatment for two groups: Placebo (N=147) and Atuzosin hydrochloride extended-release tablets (N=136). The x-axis represents the treatment duration in days, and the y-axis represents the peak urine flow rate in mL/s. The figure suggests that the Atuzosin group had a higher mean change in peak urine flow rate than the Placebo group. The asterisk (*) next to the x-axis label probably indicates statistical significance.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
The text appears to be a graphical representation of a clinical trial comparing the effects of Placebo and Alfuzosin hydrochloride extended-release tablets on Peak Urine Flow Rate, with N=150 and N=151 respectively. The x-axis shows the number of days of treatment (14, 28, 56, and 84) and the y-axis depicts the Mean Change from Baseline in Peak Urine Flow Rate (in mL/s). The graph shows no statistically significant difference between the two treatments (NS p >0.05).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.